Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes

Journal of Clinical Oncology

Volumn 23, Issue 1, 2005, Pages 41-48

  Cristofanilli, Massimo ^a   Gonzalez Angulo, Ana ^a   Sneige, Nour ^a   Kau, Shu Wan ^a   Broglio, Kristine ^a   Theriault, Richard L ^a   Valero, Vicente ^a   Buzdar, Aman U ^a   Kuerer, Henry ^a   Buccholz, Thomas A ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; TAXANE DERIVATIVE; BRIDGED COMPOUND; TAXANE; TAXOID;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT OUTCOME; ADOLESCENT; AGE; AXILLA; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; LUNG CARCINOMA; LYMPH NODE; MIDDLE AGED; MORTALITY; NEOPLASM; PAGET NIPPLE DISEASE; PATHOLOGY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AXILLA; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; DISEASE-FREE SURVIVAL; HUMANS; LYMPH NODES; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; TAXOIDS; TREATMENT OUTCOME;

EID: 16644363247     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.111     Document Type: Article

References (44)

1. The World Health Organization: The World Health Organization histological typing of breast tumors second edition. Am J Clin Pathol 78:806-816, 1982
2. Wellings SR, Jensen HM, Marcum RG: An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 55:231-273, 1975
3. Fisher ER, Gregorio RM, Fisher B, et al: The pathology of invasive breast cancer: A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol No. 4). Cancer 36:1-85, 1975
4. Wheeler JE, Enterline HT: Lobular carcinoma of the breast in situ and infiltrating. Pathol Annu 11:161-188, 1976
5. Martinez V, Azzopardi JG: Invasive lobular carcinoma of the breast: Incidence and variants. Histopathology 3:467-488, 1979
6. Foote FWJ, Stewart FW: Histologic classification of carcinoma of the breast. Surgery 19:74-99, 1946
7. Dixon JM, Anderson TJ, Page DL, et al: Infiltrating lobular carcinoma of the breast. Histopathology 6:149-161, 1982
8. du Toit RS, Locker AP, Ellis IO, et al: Invasive lobular carcinomas of the breast: The prognosis of histopathological subtypes. Br J Cancer 60:605-609, 1989
9. Sastre-Garau X, Jouve M, Asselain B, et al: Infiltrating lobular carcinoma of the breast: Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77:113-120, 1996
10. Harris M, Howell A, Chrissohou M, et al: A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer 50:23-30, 1984
11. Lamovec J, Bracko M: Metastatic pattern of infiltrating lobular carcinoma of the breast: An autopsy study. J Surg Oncol 48:28-33, 1991
12. Rechner RE: Histologic variants of infiltrating lobular carcinoma of the breast. Hum Pathol 6:373-378, 1975
13. Cleton-Jansen AM: E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: Different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res 4:5-8, 2002
14. de Leeuw WJ, Berx G, Vos CB, et al: Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 183:404-411, 1997
15. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
16. Korkola JE, DeVries S, Fridlyand J, et al: Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 63:7167-7175, 2003
17. Silverstein MJ, Waisman JR, Gamagami P, et al: Intraductal carcinoma of the breast (208 cases): Clinical factors influencing treatment choice. Cancer 66:102-108, 1990
18. Toikkanen S, Pylkkanen L, Joensuu H: Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 76:1234-1240, 1997
19. Rouzier RD, Youmsi E, Delaloge S, et al: Predictors of breast-conserving surgery after epirubicin-based neoadjuvant chemotherapy for large breast carcinoma. Proc Am Soc Clin Oncol 22:38a, 2003 (abstr 151)
20. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
21. Rouzier R, Extra JM, Klijanienko J, et al: Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20:1304-1310, 2002
22. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
23. Buzdar AU, Singletary SE, Theriault RL, et al: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17:3412-3417, 1999
24. Green MC, Buzdar AU, Smith T, et al: Weekly paclitaxel followed by FAC in the neoadjuvant setting provides improved pathologic complete remission rates compared to standard paclitaxel followed by FAC therapy-preliminary results of an ongoing prospective randomized trial. Proc Am Soc Clin Oncol 20:33a, 2001 (abstr 129)
25. Dhingra K, Esparza-Guerra L, Valero V, et al: A phase III randomized trial of dose-intensive neoadjuvant 5FU, doxorubicin, cyclophosphamide (FAC) with G-CSF (filgrastin) in locally advanced breast cancer (LABC): Efficacy and safety data. Proc Amer Soc Clin Oncol 18:74a, 1999 (abstr 278)
26. Hortobagyi GN, Holmes FA, Frye D, et al: Comparison of two adjuvant chemotherapy programs for locally advanced breast cancer: A prospective randomized trial. Proc Am Soc Clin Oncol 9:21, 1990 (abstr 77)
27. Black MM, Speer FD: Nuclear structure in cancer tissues. Surg Gynecol Obstet 105:97-102, 1957
28. Valero V, Buzdar AU, McNeese M, et al: Primary chemotherapy in the treatment of breast cancer: The University of Texas M.D. Anderson Cancer Center experience. Clin Breast Cancer 3:S63-S68, 2002 (suppl 2)
29. Kaufmann M, von Minckwitz G, Smith R, et al: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 21:2600-2608, 2003
30. Hortobagyi GN, Ames FC, Buzdar AU, et al: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507-2516, 1988
31. Bonadonna G, Valagussa P, Brambilla C, et al: Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100, 1998
32. Buzdar AU, Valero V, Theriault RL, et al: Pathologic complete response to chemotherapy is related with hormone receptor status. Breast Cancer Res Treat 82:S69a, 2003 (suppl 1)
33. Makris A, Powles TJ, Ashley SE, et al: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9:1179-1184, 1998
34. Hutcheon AW, Heys SD, Sarkar TK: Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat 79:S19-S24, 2003 (suppl 1)
35. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174, 2003
36. Cocquyt VF, Blondeel PN, Depypere HT, et al: Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 29:361-367, 2003
37. Bonadonna G, Veronesi U, Brambilla C, et al: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539-1545, 1990
38. MacGrogan G, Mauriac L, Durand M, et al: Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 74:1458-1465, 1996
39. Calais G, Berger C, Descamps P, et al: Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 74:1283-1288, 1994
40. Horobin JM, Preece PE, Dewar JA, et al: Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg 78:213-217, 1991
41. Dixon JM, Renshaw L, Bellamy C, et al: The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: A randomized, double-blind, single-center study. Clin Cancer Res 6:2229-2235, 2000
42. Dixon JM, Love CDB, Bellamy COC, et al: Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 66:191-199, 2001
43. Eiermann W, Paepke S, Appfelstaedt J, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12:1527-1532, 2001
44. Smith I, Dowsett M, on behalf of the IMPACT trialists: Comparison of anastrozole vs. tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive breast cancer in postmenopausal women: The IMPACT trial. Breast Cancer Res Treat 82:S5, 2003 (suppl 1)